DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (AMEX: AXK) announced today that it has signed an agreement with BD (Becton, Dickinson and Company) with respect to Accelr8’s BACcel™ rapid pathogen diagnostics platform. Under the agreement, BD will fund a research program at Accelr8 through September 30, 2009. The research program includes mutually agreed milestones to support BD’s product development planning. BD has the option, during or at the conclusion of the research program, to exclusively license Accelr8’s intellectual property in the field of infectious diseases diagnostics. Accelr8 would retain the right to commercialize its technology for other applications.
